A drug related to the class of proton pump inhibitors, most effective in reducing gastric acid secretion, was approved for the use in children.
The drug under the brand name “Nexium” is used in the treatment of gastroesophageal reflux disease (GORD/GERD).
The FDA has approved the drug for the short-term use in children ages 1 to 11, while previously the age group ranged 12-17.
The drug is available as delayed-release capsules in the United States or as delayed release tablets in Australia and Canada (containing esomeprazole magnesium) in strengths of 20 mg and 40 mg for adults; and as esomeprazole sodium for intravenous injection/infusion.
The approved doses for children are half of those approved for older children.
Nexium is produced by AstraZeneca and is said to be the third biggest selling pharmaceutical drug in the world.